Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells
Shimizu et al., Scientific Reports, doi:10.1038/s41598-022-19993-w
Shimizu et al., Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and.., Scientific Reports, doi:10.1038/s41598-022-19993-w
Sep 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
In Vitro study showing that casirivimab/imdevimab may induce antibody-dependent enhancement (ADE) within a specific concentration range. No ADE was observed for sotrovimab.
Shimizu et al., 16 Sep 2022, Japan, peer-reviewed, 12 authors.
Contact: kmiyazaki@micantechnologies.com, shioda@biken.osaka-u.ac.jp.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Abstract: www.nature.com/scientificreports OPEN Reevaluation of antibody‑dependent enhancement of infection in anti‑SARS‑CoV‑2 therapeutic antibodies and mRNA‑vaccine antisera using FcR‑ and ACE2‑positive cells Jun Shimizu1, Tadahiro Sasaki2, Ritsuko Koketsu2, Ryo Morita3, Yuka Yoshimura1, Ami Murakami1, Yua Saito1, Toshie Kusunoki1, Yoshihiro Samune2, Emi E. Nakayama2, Kazuo Miyazaki1* & Tatsuo Shioda2* Many therapeutic antibodies (Abs) and mRNA vaccines, both targeting SARS-CoV-2 spike protein (S-protein), have been developed and approved in order to combat the ongoing COVID-19 pandemic. In consideration of these developments, a common concern has been the potential for Ab-dependent enhancement (ADE) of infection caused by inoculated or induced Abs. Although the preventive and therapeutic effects of these Abs are obvious, little attention has been paid to the influence of the remaining and dwindling anti-S-protein Abs in vivo. Here, we demonstrate that certain monoclonal Abs (mAbs) approved as therapeutic neutralizing anti-S-protein mAbs for human usage have the potential to cause ADE in a narrow range of Ab concentrations. Although sera collected from mRNAvaccinated individuals exhibited neutralizing activity, some sera gradually exhibited dominance of ADE activity in a time-dependent manner. None of the sera examined exhibited neutralizing activity against infection with the Omicron strain. Rather, some ADE of Omicron infection was observed in some sera. These results suggest the possible emergence of adverse effects caused by these Abs in addition to the therapeutic or preventive effect. Therapeutic Ab drugs targeting SARS-CoV-2 S-protein have shown high preventive efficacy against disease ­development1–3. In addition, current SARS-CoV-2 mRNA vaccines for humans also target the S-protein on viruses as a critical a­ ntigen4. These mRNA vaccines generate robust neutralizing A ­ bs5–7, but for both Ab drugs and vaccines targeting the S-protein, the possible induction of Ab-dependent enhancement (ADE) of infection is a ­concern8–11. Recent reports have demonstrated that neutralizing mAbs against S-protein can exhibit ADE activity in a limited window of Ab c­ oncentrations12–14. An important issue requiring reconsideration is that the cells used to evaluate ADE potential are different in each report. In many cases, Fc-receptor (FcR)-positive and angiotensin-converting enzyme 2 (ACE2, the major receptor for SARS-CoV-215–17)-negative cells lines (Raji, THP-1, and K562) are used as host cells for infection of SARS-CoV-2 pseudo-viruses expressing S-protein or authentic SARS-CoV-212–14,18,19. These reports have demonstrated that some anti-S protein mAbs have the potential to induce ADE of infection. The observed ADE can be blocked in the presence of FcR-blocker, demonstrating FcR dependence. Likewise, the Ab drugs casirivimab and ­imdevimab1,20,21, which target the SARSCoV-2 S-protein, have also been evaluated by using FcR-positive and ACE2-negative cell lines (U937, THP-1, 1 MiCAN Technologies Inc, KKVP 1‑36, Goryo‑ohara, Nishikyo‑Ku, Kyoto 615‑8245, Japan. 2Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, 3‑1, Yamada‑oka, Suita, Osaka 565‑0871, Japan. 3Osaka City Juso Hospital, 2‑12‑27, Nonakakita, Yodogawa‑ku, Osaka 532‑0034, Japan. *email: kmiyazaki@micantechnologies.com; shioda@biken.osaka-u.ac.jp Scientific Reports | (2022) 12:15612 |..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit